Pathway

Mood (serotonin)

Serotonin

The Wellbeing Molecule

20 blends on this site modulate it.

Also searched as Serotonin.

You want it in healthy balance: sound serotonin tone underlies stable mood and restful sleep.

In depth

Serotonin — the neurotransmitter of mood and satiety, and the precursor the body converts to melatonin for sleep.

What drives it

Gut barrier increases it.

Yano 2015, Cell 161:264 — indigenous gut microbiota promote serotonin (5-HT) biosynthesis from colonic enterochromaffin cells, supplying 5-HT to mucosa and circulation. PMID 25860609. Convergent, and the mechanism is dual: specific probiotic species facilitate the metabolic conversion of tryptophan to serotonin, and separately suppress MAO-A activity via short-chain fatty acids — raising serotonin bioavailability by both synthesis and reduced degradation. The reviewers frame this as bidirectional regulation of synthetic and degrading enzymes. Shared caveats on this whole row: (1) the route to the brain is not free — gut-derived neurotransmitters reach targets via the bloodstream and must cross the blood-brain barrier; elevated plasma 5-HT can itself raise BBB permeability, temporarily letting plasma 5-HT enter the CNS, so the barrier is a variable not a constant. (2) much of this literature is association — the reviews state plainly that the association studies linking microbiota to depression did not provide evidence on aetiology. (3) The enteric nervous system hosts more than 30 neurotransmitters; any single arrow is one strand of a dense web. PMID 25860609

Tryptophan balance reduces it.

The arithmetic is the argument: the serotonin route consumes only about 1% of tryptophan, while the kynurenine pathway takes roughly 95% (PMC9142829). So a modest shift toward kynurenine starves a very small pathway of its only precursor. Shown by blocking it — after experimental brain injury, synaptosomal 5-HT fell and the fall was neutralized by the IDO inhibitor 1-methyl tryptophan (PMC9907831); IDO-inhibitor treatment likewise prevents inflammation-induced depressive-like behavior in rodents (PMC5753541). The limit, and it is a human null: a clinical study measuring tryptophan, kynurenine and the KYN/TRP ratio in serum and CSF found NO significant difference between depressed patients and controls (PMC5632654). The mechanism is solid in animals and in principle; the human biomarker case is not settled. PMC9142829

Calm reduces it.

GABA inputs inhibit raphe 5-HT neuron firing — the brake does not only act downstream in the amygdala, it reaches the source of forebrain serotonin. And the loop closes back: the GABAergic afferents may express 5-HT1B receptors that inhibit GABA release, so serotonin can disinhibit its own drive; raphe 5-HT neurons additionally autoinhibit through 5-HT1A autoreceptors. Stress reaches this junction too: raphe 5-HT neurons express glucocorticoid receptors, and chronic corticosterone alters 5-HT7-receptor-mediated modulation of GABAergic transmission in the DRN — which is a further unchecked pair, hpa? serotonin. PMC6267141

Alertness chemical increases it.

10.1038/s41386-024-01824-3 — ,In vivo the levels of norepinephrine and serotonin in the dorsal raphe covary positively, because noradrenergic input drives the serotonin neurons to fire action potentials and release serotonin via Gq-coupled alpha-1 adrenergic receptors. Channelrhodopsin circuit mapping shows sufficiency: activation of locus-coeruleus-derived noradrenergic axon terminals was sufficient to produce an alpha-1-receptor epsc in dorsal raphe serotonin neurons. Presynaptic brake: alpha-2 adrenergic receptors inhibit that epsc by cutting norepinephrine release. doi 10.1038/s41386-024-01824-3

Endocannabinoid tone reduces it.

endocannabinoids suppress excitatory synaptic transmission to dorsal raphe serotonin neurons through activation of presynaptic CB1 receptors (Haj-Dahmane & Shen 2009), and serotonin release is inhibited via presynaptic CB1 receptors (Nakazi 2000). The signaling is tonic, not only evoked: both 2-AG and anandamide are constitutively released in the drn, exerting tonic control of glutamatergic transmission onto 5-HT neurons, with the magnitude set by overall network activity — silencing the network abolishes the tonic signal. And the two endocannabinoids are not interchangeable: tonic 2-AG, but not anandamide, modulates synaptic plasticity, and it does so not through canonical cannabinoid receptors but through intracellular PPAR-gamma, blocking potentiation by inhibiting the NO/sGC/pkg pathway. PMC8273699

Lowers cortisol reduces it.

Raphe 5-HT neurons express glucocorticoid receptors, and corticosterone produces glucocorticoid-receptor-mediated inhibition of 5-HT1A autoreceptor functioning in the dorsal raphe (Laaris 1995). Chronic corticosterone additionally alters 5-HT7-receptor-mediated modulation of GABAergic transmission in the DRN, an effect ameliorated by the 5-HT7 antagonist SB 269970 — a pharmacological rescue. The sign is not simple and is recorded as such: blunting an inhibitory autoreceptor would DISINHIBIT firing, while the wider corticosteroid-serotonin literature treats the net effect on stress-related disorders as impairing. What is certain is that stress hormones rewrite the responsiveness of the serotonin source itself, not merely its downstream targets. doi 10.1007/s00213-018-5045-y

Quiets overexcitation increases it.

The mechanism is a glutamate receptor: alpha-1-mediated excitatory transmission is carried by the ionotropic glutamate receptor HOMOLOG cation channel delta glutamate receptor 1 (GluD1), which is constitutively active under basal conditions carrying tonic inward current, and alpha-1 activation augments that tonic current. And deleting it causes anxiety: loss of dorsal raphe GluD1R channels produces an anxiogenic phenotype — a direct behavioral readout, not an inferred one. GluD1 is responsible for the alpha-1-dependent persistent pacemaker-type firing of raphe neurons. tonic noradrenergic input is stated to be required for 5-HT neurons to fire and release serotonin, so this channel sits on the critical path of the whole serotonergic output. PMC7180053

The Two-Faced Peptide reduces it.

Acute KOR activation inhibits serotonergic neuronal excitability within the dorsal raphe by two routes at once — presynaptic inhibition of excitatory synaptic transmission and postsynaptic activation of inwardly-rectifying potassium conductance. Both the input and the cell itself are damped. Site-specific causal proof: injecting the KOR antagonist norBNI into the dorsal raphe blocked the aversive response to a systemic KOR agonist and blocked stress-induced reinstatement. The dysphoric effect of kappa activation requires the raphe — block it there and systemic drug loses its aversive quality. This is the cellular content of the classic finding that the dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system (Land 2008). And repeated stress changes the machinery, not just the signal: repeated stress dysregulates KOR signaling in the dorsal raphe through a p38-alpha MAPK-dependent mechanism — so the same peptide acts differently on a stressed brain than a naive one, the same caveat already recorded on the Dynorphin → GABA link for drug history. doi 10.1073/pnas.0910705106

Monoamine breakdown reduces it.

10.3389/fphar.2020.593416 — Serotonin and norepinephrine are substrates of MAO-A. MAO-A is distributed mainly in the placenta, gut and liver. Degradative enzyme, so the edge is inhibitory: more MAO-A activity, less serotonin. StatPearls NBK539848 — Monoamine Oxidase Inhibitors. doi 10.3389/fphar.2020.593416

What it drives

It increases Moves everything along.

Raising available serotonin in healthy volunteers with the reuptake inhibitor paroxetine shortened migrating motor complex periodicity from about 81 to 67 minutes, increased phase III propagation velocity and cut orocaecal transit time from about 70 to 48 minutes, so more serotonin signalling meant faster gut transit. doi 10.1136/gut.35.4.496 · PMID 8174987

It increases Mood.

Delgado 2000 — the monoamine hypothesis: serotonin deficiency underlies depressed mood. PMID 10775018. A systematic umbrella review — the highest level of evidence synthesis — concluded there is NO consistent evidence of an association between serotonin and depression (Moncrieff, Cooper, Stockmann, Amendola, Hengartner & Horowitz 2022, Molecular Psychiatry, doi 10.1038/s41380-022-01661-0). The specifics: a meta-analysis of plasma serotonin showed NO relationship with depression (n=1,869) and found that lowered serotonin was associated with antidepressant use; 5-HT1A receptor-binding (largest n=561) and SERT-binding (largest n=1,845) meta-analyses showed weak and inconsistent evidence with prior antidepressant use not reliably excluded; and tryptophan depletion produced NO effect in most healthy volunteers (n=566), with weak evidence only in those with a family history (n=75). Separately, a meta-analysis of monoamine-depletion studies concluded monoamines alone ARE not sufficient to cause depression and depression has NO direct causal relation with monoamine depletion (Ruhe 2007, Mol Psychiatry 12:331). The dispute is live and both sides ARE cited here: Jauhar and colleagues replied under the title 'A leaky umbrella has little value: evidence clearly indicates the serotonin system is implicated in depression' (doi 10.1038/s41380-023-02095-y), and methodological critiques argue Moncrieff et al. mixed study types inappropriately and used unclear primary-study selection criteria (PMC9957868). One finding both sides accept: depletion did lower mood in patients with MDD in remission — the system matters in the vulnerable, not in everyone. doi 10.1038/s41380-022-01661-0 · PMID 10775018 · PMC9957868

It increases Sleep hormone.

Serotonin modulates melatonin synthesis, PNAS 2021 — serotonin induces AANAT, the rate-limiting step in its conversion to melatonin. doi 10.1073/pnas.2113852118

It increases Gut-brain signal.

The gut talks to the brain in serotonin: enterochromaffin cells synthesize about 95% of the body's 5-HT and release it in response to mechanical or chemical stimulation of the gut, whereupon it acts on 5-HT3 receptors on the terminals of vagal afferents to increase vagal afferent firing (PMC4625078, PMC5165017). The vagus is roughly 70-80% sensory, so this is predominantly gut reporting to brain rather than brain commanding gut — and 5-HT3 signaling on that route carries satiety and visceral sensation. PMC4625078

It increases Digestion.

The same enterochromaffin 5-HT acts locally before it ever reaches the brain: EC-cell serotonin has direct physiological effects on gut motility, secretion and visceral sensation, and abnormal 5-HT regulation is implicated in gastrointestinal disorders and inflammatory bowel disease (PMC5165017). EC cells are mechanosensors — they translate the physical force of peristalsis into 5-HT and ATP release. PMC5165017

It reduces Calm under stress.

Serotonin reuptake inhibitors ARE an evidence-based first-line pharmacological treatment for anxiety disorders and current practice guidelines recommend SSRIs or SNRIs as preferred first-line therapy. Genetic variation in the serotonin transporter gene SLC6A4 is linked to increased anxiety risk, and 5-HTT, 5-HT1A and 5-HT2 receptors are the studied targets. A weak case in depression does not transfer to anxiety, and the reverse is equally true. The same literature states the these medications fail to improve anxiety symptoms in a significant proportion of patients, and the relation between the genetic background of these targets and anxiety symptoms is largely unknown. doi 10.3389/fpsyt.2020.548505 · PMC3677985

It increases Stress-relapse axis.

Serotonin and crf both sat on the anxiety enumeration as parallel items. They are not parallel. Serotonin from the dorsal raphe enhances fear and anxiety and activates a subpopulation of crf neurons in the bed nucleus of the stria terminalis. The route is specified to the receptor: 5-HT-drn projections to the bnst act at 5-HT2C receptors to engage a crf-bnst inhibitory microcircuit that silences anxiolytic bnst outputs to the ventral tegmental area and lateral hypothalamus. And the authors name the clinical phenomenon it explains: this crf-bnst inhibitory circuit underlies aversive behavior following acute exposure to SSRIs — the initial worsening every patient is warned about. A single arrow was hiding two opposite behaviors. PMC5124365

It increases Endocannabinoid tone.

Serotonin builds its own brake and the brake then shuts serotonin off. One receptor subtype is running both the anxiogenic CRF arm and this self-limiting endocannabinoid arm. And the endocannabinoid return arm is independently characterized: CB1 inhibition of excitatory currents onto raphe 5-HT neurons is presynaptic, shown by increased paired-pulse ratio and coefficient of variation and by inhibition of mEPSC frequency but not amplitude. doi 10.20517/and.2023.19 · PMC2766225

It increases Sleep.

10.1038/s41598-021-92913-6 — the serotonergic dorsal raphe is wake-active — which surprises people who associate serotonin with rest. The cleanest demonstration is also the oldest and simplest: cooling of the nucleus raphe DORSALIS induces sleep in the CAT. Reduce that nucleus’ activity and the animal falls asleep. Converging: an orexin-2-selective antagonist reduced Fos-positive serotonergic neurons in the dorsal raphe alongside its hypnotic effect. The GABAergic VLPO neurons inhibit both the orexin system and the ascending arousal system; the arousal nuclei inhibit the VLPO back. A flip-flop has no comfortable middle — which is why sleep onset is abrupt rather than gradual, and why these arrows are drawn inhibitory as a class. doi 10.1038/s41598-021-92913-6

It reduces Supports weight management.

The mechanism is explicit: fenfluramine and DEXFENFLURAMINE ARE serotonergic drugs which cause the release of serotonin to suppress appetite and reduce food intake. Both were individually FDA-approved. The mixed reuptake inhibitor sibutramine achieved 4.5 kg weight reduction in meta-analysis. And the failure mode was cardiac and structural: fenfluramine and DEXFENFLURAMINE were withdrawn because of heart valve damage. Not a tolerability issue — irreversible organ injury from a weight-loss drug. The pattern across this pathway is the point: every centrally-acting appetite SUPPRESSANT that produced meaningful weight loss also produced a serious off-target harm, and each failed in a different organ — serotonergic (fenfluramine: heart valve damage), mixed serotonin-norepinephrine (sibutramine: major adverse cardiovascular events in SCOUT), and endocannabinoid (rimonabant: psychiatric disorders). And none changed the SETPOINT: patients were unable to retain weight loss once therapy was discontinued. PMC3083904

It reduces Neurovascular calm.

Serotonin depletion is implicated in many neurological disorders and has been shown to exacerbate CSD-evoked pain at the cortical level. This is the mechanistic anchor under the triptan class, which are 5-HT agonists - and the CGRP evidence has the same shape: elevated CGRP levels in the jugular vein during a migraine attack and its normalization by the anti-migraine drug SUMATRIPTAN. PMID 36361791 · PMC10933035

It reduces Sexual function.

Named across five reviews of erectile and female arousal physiology. Key contributors include reduced nitric oxide bioavailability due to endothelial oxidative stress and inflammation, diminished cavernosal smooth muscle content leading to impaired veno-occlusion, and increased arterial stiffness compounded by metabolic disorders. doi 10.21037/tau-2025-419 · PMID 19138376 · PMC11988752

It reduces Female libido.

It increases Gut barrier.

10.1038/nrgastro.2013.105 — The aging outcome lists the thirteen hallmarks themselves, each mapped to its pathway and labeled with its hallmark number. (from the reviews of this outcome). doi 10.1038/nrgastro.2013.105